Sydney mother celebrates miracle baby after traumatic journey to motherhood

Skip to navigation Skip to content Skip to footer View text version of this page Help using this website – Accessibility statement Join today and you can easily save your favourite articles, join in the conversation and comment, plus select which news your want direct to your inbox. Join today and you can easily save your favourite articles, join in the conversation and comment, plus select which news your want direct to your inbox.

Threshold Pharmaceuticals and National Cancer Institute to Collaborate on Drug Candidate TH-3424

Threshold Pharmaceuticals, Inc. , a clinical-stage biopharmaceutical company developing novel therapies for cancer, today announced that it has entered into a collaboration with the National Cancer Institute , part of the National Institutes of Health , to study TH-3424, the company’s new drug candidate for the treatment of cancer. The collaboration will explore the effects of TH-3424 against T-cell acute lymphoblastic leukemia xenograft cell lines with high AKR1C3 expression.